{"id":631,"date":"2021-08-25T14:56:00","date_gmt":"2021-08-25T18:56:00","guid":{"rendered":"https:\/\/www.napra.ca\/?p=631"},"modified":"2022-09-14T12:03:48","modified_gmt":"2022-09-14T16:03:48","slug":"politique-relative-aux-medicaments-nayant-pas-fait-lobjet-dun-examen-furoate-de-mometasone","status":"publish","type":"post","link":"https:\/\/www.napra.ca\/fr\/politique-relative-aux-medicaments-nayant-pas-fait-lobjet-dun-examen-furoate-de-mometasone\/","title":{"rendered":"Politique relative aux m\u00e9dicaments n\u2019ayant pas fait l\u2019objet d\u2019un examen \u2013 Furoate de mom\u00e9tasone"},"content":{"rendered":"\n<p>L\u2019Association nationale des organismes de r\u00e9glementation de la pharmacie (ANORP) a re\u00e7u des questions sur la classification de la mom\u00e9tasone en vaporisateur nasal. Le furoate de mom\u00e9tasone pour le traitement des sympt\u00f4mes de la rhinite allergique, administr\u00e9 par vaporisation nasale \u00e0 raison d&rsquo;une dose de 50 microgrammes (mcg)\/jet, destin\u00e9 \u00e0 des personnes \u00e2g\u00e9es de 12 ans ou plus, est class\u00e9 dans l\u2019annexe I des Annexes nationales de m\u00e9dicaments (ANM) bien qu\u2019il ne figure plus sur la Liste des drogues sur ordonnance. Ceci est d\u00fb au fait que la\u00a0<a href=\"https:\/\/www.napra.ca\/fr\/politiques-soutenant-les-anm\/\" data-type=\"page\" data-id=\"1526\">Politique relative aux m\u00e9dicaments n\u2019ayant pas fait l\u2019objet d\u2019un examen<\/a>\u00a0s\u2019y applique.<\/p>\n\n\n\n<p>Depuis l\u2019\u00e9tablissement des ANM de l\u2019ANORP, il est arriv\u00e9, dans quelques cas isol\u00e9s, que le fabricant d\u2019un nouveau m\u00e9dicament sans ordonnance ou d\u2019un m\u00e9dicament d\u00e9r\u00e9glement\u00e9 (qui est pass\u00e9 d\u2019un m\u00e9dicament sur ordonnance \u00e0 un m\u00e9dicament sans ordonnance) n\u2019ait pas demand\u00e9 au Comit\u00e9 consultatif national sur les annexes de m\u00e9dicaments (CCNAM) de recommander sa classification dans les ANM; par cons\u00e9quent, le m\u00e9dicament n\u2019a pas \u00e9t\u00e9 attribu\u00e9 \u00e0 l\u2019une des ANM. Cela peut se produire, entre autres raisons, parce que le fabricant d\u00e9cide de ne pas commercialiser le nouveau m\u00e9dicament sans ordonnance au Canada ou ne conna\u00eet pas le processus national de classification de m\u00e9dicaments.<\/p>\n\n\n\n<p>La\u00a0<a href=\"https:\/\/www.napra.ca\/fr\/politiques-soutenant-les-anm\/\" data-type=\"page\" data-id=\"1526\">Politique relative aux m\u00e9dicaments n\u2019ayant pas fait l\u2019objet d\u2019un examen<\/a>\u00a0indique qu\u2019en l\u2019absence d\u2019un examen du CCNAM et de donn\u00e9es appuyant l\u2019attribution d\u2019un statut particulier \u00e0 un m\u00e9dicament sans ordonnance, les m\u00e9dicaments sans ordonnance d\u00e9r\u00e9glement\u00e9s ou r\u00e9cemment approuv\u00e9s par le gouvernement f\u00e9d\u00e9ral sont class\u00e9s dans l\u2019<strong>annexe I<\/strong>\u00a0du mod\u00e8le national de classification des m\u00e9dicaments et sont r\u00e9pertori\u00e9s comme tels.<\/p>\n\n\n\n<p>Le furoate de mom\u00e9tasone pour le traitement des sympt\u00f4mes de la rhinite allergique, administr\u00e9 par vaporisation nasale \u00e0 raison d&rsquo;une dose de 50 microgrammes (mcg)\/jet, destin\u00e9 \u00e0 des personnes \u00e2g\u00e9es de 12 ans ou plus, fut retir\u00e9e de la Liste des drogues sur ordonnance de Sant\u00e9 Canada le 12 ao\u00fbt 2015. Par cons\u00e9quent, et conform\u00e9ment \u00e0 la\u00a0<a href=\"https:\/\/www.napra.ca\/fr\/politiques-soutenant-les-anm\/\" data-type=\"page\" data-id=\"1526\">Politique relative aux m\u00e9dicaments n\u2019ayant pas fait l\u2019objet d\u2019un examen<\/a>\u00a0de l\u2019ANORP, ce m\u00e9dicament fut class\u00e9 dans l\u2019annexe I des ANM le 23 ao\u00fbt 2015. Il demeure r\u00e9pertori\u00e9 comme tel depuis lors.<\/p>\n\n\n\n<p>Ainsi, ce m\u00e9dicament n\u00e9cessite toujours une ordonnance dans les\u00a0<a href=\"https:\/\/www.napra.ca\/fr\/application-des-anm-au-canada\/\" data-type=\"page\" data-id=\"1531\">provinces et territoires qui appliquent les ANM<\/a>. La classification de ce m\u00e9dicament dans les ANM ne peut changer que si l\u2019ANORP re\u00e7oit une demande de classification de m\u00e9dicament (habituellement de la part d\u2019un promoteur ou d\u2019un fabricant) pour un examen par le CCNAM.\u00a0<\/p>\n\n\n\n<p>De plus, puisque les ANM sont mises en \u0153uvre de mani\u00e8re l\u00e9g\u00e8rement diff\u00e9rente selon la province ou le territoire, il pourrait y avoir des exceptions \u00e0 la classification de certains m\u00e9dicaments dans certaines provinces ou certains territoires (de plus amples renseignements sont disponibles sur le\u00a0<a href=\"https:\/\/www.napra.ca\/fr\/application-des-anm-au-canada\/\" data-type=\"page\" data-id=\"1531\">site Web de l\u2019ANORP<\/a>). Il est conseill\u00e9 de s\u2019adresser \u00e0 l\u2019<a href=\"https:\/\/www.napra.ca\/fr\/organismes-de-reglementation-de-la-pharmacie\/\" data-type=\"page\" data-id=\"1549\">organisme de r\u00e9glementation de la pharmacie<\/a>\u00a0(habituellement l\u2019ordre des pharmaciens) de la province ou du territoire en question pour obtenir des renseignements pr\u00e9cis au sujet des r\u00e8glements qui s\u2019appliquent \u00e0 la classification de m\u00e9dicaments dans cette province ou ce territoire.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019Association nationale des organismes de r\u00e9glementation de la pharmacie (ANORP) a re\u00e7u des questions sur la classification de la mom\u00e9tasone en vaporisateur nasal. Le furoate de mom\u00e9tasone pour le traitement [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":625,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_uag_custom_page_level_css":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[18],"tags":[],"class_list":["post-631","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mises-a-jour-des-anm"],"acf":[],"uagb_featured_image_src":{"full":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-FAQ-FR.png",660,440,false],"thumbnail":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-FAQ-FR-150x150.png",150,150,true],"medium":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-FAQ-FR-300x200.png",300,200,true],"medium_large":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-FAQ-FR.png",660,440,false],"large":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-FAQ-FR.png",660,440,false],"1536x1536":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-FAQ-FR.png",660,440,false],"2048x2048":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-FAQ-FR.png",660,440,false],"gform-image-choice-sm":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-FAQ-FR.png",300,200,false],"gform-image-choice-md":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-FAQ-FR.png",400,267,false],"gform-image-choice-lg":["https:\/\/www.napra.ca\/wp-content\/uploads\/2022\/08\/news-NDS-FAQ-FR.png",600,400,false]},"uagb_author_info":{"display_name":"Stephanie Smith","author_link":"https:\/\/www.napra.ca\/fr\/author\/stephflow\/"},"uagb_comment_info":0,"uagb_excerpt":"L\u2019Association nationale des organismes de r\u00e9glementation de la pharmacie (ANORP) a re\u00e7u des questions sur la classification de la mom\u00e9tasone en vaporisateur nasal. Le furoate de mom\u00e9tasone pour le traitement [&hellip;]","_links":{"self":[{"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/posts\/631","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/comments?post=631"}],"version-history":[{"count":0,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/posts\/631\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/media\/625"}],"wp:attachment":[{"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/media?parent=631"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/categories?post=631"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.napra.ca\/fr\/wp-json\/wp\/v2\/tags?post=631"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}